SAB Biotherapeutics regains Nasdaq minimum bid price compliance after reverse split

SAB Biotherapeutics, Inc.

Received Nasdaq notice on Jan 23, 2024 confirming regained compliance with bid price rule.
Company conducted a 1-for-10 reverse stock split on Jan 5, 2024 to help meet the $1.00 minimum close.
Common shares met $1.00 closing bid for 10 consecutive trading days, ending the deficiency.
Prior non-compliance notice was issued Jan 23, 2023; Nasdaq has now closed the matter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.